K. Stender

P.3.026 Fixed doses of escitalopram and paroxetine for the treatment of social anxiety disorder (SAD)

M. Lader, R. Nil, K. Stender, 2003, European Neuropsychopharmacology.

Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.

P. Mecocci, M. Emre, K. Stender, 2008, Journal of Alzheimer's disease : JAD.

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post‐hoc analyses of ADAS‐cog and SIB total and single‐item scores from six randomized, double‐blind, placebo‐controlled studies

P. Mecocci, A. Bladström, K. Stender, 2009, International journal of geriatric psychiatry.

Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: Randomised, double‐blind, placebo‐controlled, fixed‐dose study

M. Lader, R. Nil, K. Stender, 2004, Depression and anxiety.

Memantine benefits functional abilities in moderate to severe Alzheimer’s disease

B. Winblad, S. Gauthier, D. Åström, 2010, The journal of nutrition, health & aging.

MEMANTINEBENEFITSFUNCTIONALABILITIESIN MODERATE TOSEVEREALZHEIMER'S DISEASE

B. Winblad, S. Gauthier, D. Åström, 2010 .